|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Brekelmans CT, Seynaeve C, Bartels CC, et
al: Effectiveness of breast cancer surveillance in BRCA1/2 gene
mutation carriers and women with high familial risk. J Clin Oncol.
19:924–930. 2001.PubMed/NCBI
|
|
3
|
Harris L, Fritsche H, Mennel R, et al:
American Society of Clinical Oncology 2007 update of
recommendations for the use of tumor markers in breast cancer. J
Clin Oncol. 25:5287–5312. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tyers M and Mann M: From genomics to
proteomics. Nature. 422:193–197. 2003. View Article : Google Scholar
|
|
5
|
Elrick MM, Walgren JL, Mitchell MD and
Thompson DC: Proteomics: recent applications and new technologies.
Basic Clin Pharmacol Toxicol. 98:432–441. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Banks RE, Dunn MJ, Hochstrasser DF, et al:
Proteomics: new perspectives, new biomedical opportunities. Lancet.
356:1749–1756. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li J, Zhang Z, Rosenzweig J, Wang YY and
Chan DW: Proteomics and bioinformatics approaches for
identification of serum biomarkers to detect breast cancer. Clin
Chem. 48:1296–1304. 2002.PubMed/NCBI
|
|
8
|
Mathelin C, Cromer A, Wendling C,
Tomasetto C and Rio MC: Serum biomarkers for detection of breast
cancers: A prospective study. Breast Cancer Res Treat. 96:83–90.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baskin Y and Yigitbasi T: Clinical
proteomics of breast cancer. Curr Genomics. 11:528–536. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huijbers A, Velstra B, Dekker TJ, et al:
Proteomic serum biomarkers and their potential application in
cancer screening programs. Int J Mol Sci. 11:4175–4193. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Paweletz CP, Trock B, Pennanen M, et al:
Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF:
potential for new biomarkers to aid in the diagnosis of breast
cancer. Dis Markers. 17:301–307. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li J, Zhao J, Yu X, et al: Identification
of biomarkers for breast cancer in nipple aspiration and ductal
lavage fluid. Clin Cancer Res. 11:8312–8320. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pawlik TM, Fritsche H, Coombes KR, et al:
Significant differences in nipple aspirate fluid protein expression
between healthy women and those with breast cancer demonstrated by
time-of-flight mass spectrometry. Breast Cancer Res Treat.
89:149–157. 2005. View Article : Google Scholar
|
|
14
|
de Noo ME, Deelder A, van der Werff M,
Ozalp A, Mertens B and Tollenaar R: MALDI-TOF serum protein
profiling for the detection of breast cancer. Onkologie.
29:501–506. 2006.
|
|
15
|
Villanueva J, Shaffer DR, Philip J, et al:
Differential exoprotease activities confer tumor-specific serum
peptidome patterns. J Clin Invest. 116:271–284. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Engwegen JY, Gast MC, Schellens JH and
Beijnen JH: Clinical proteomics: searching for better tumour
markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci.
27:251–259. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lebrecht A, Boehm D, Schmidt M, Koelbl H
and Grus FH: Surface-enhanced laser desorption/ionisation
time-of-flight mass spectrometry to detect breast cancer markers in
tears and serum. Cancer Genomics Proteomics. 6:75–83.
2009.PubMed/NCBI
|
|
18
|
Hudson ME, Pozdnyakova I, Haines K, Mor G
and Snyder M: Identification of differentially expressed proteins
in ovarian cancer using high-density protein microarrays. Proc Natl
Acad Sci USA. 104:17494–17499. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hodgkinson VC, ElFadl D, Drew PJ, Lind MJ
and Cawkwell L: Repeatedly identified differentially expressed
proteins (RIDEPs) from antibody microarray proteomic analysis. J
Proteomics. 74:698–703. 2011. View Article : Google Scholar
|
|
20
|
Shi W, Meng Z, Chen Z, Luo J and Liu L:
Proteome analysis of human pancreatic cancer cell lines with highly
liver metastatic potential by antibody microarray. Mol Cell
Biochem. 347:117–125. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang L, Guo S, Li Y, Zhou S and Tao S:
Protein microarrays for systems biology. Acta Biochim Biophys Sin
(Shanghai). 43:161–171. 2011. View Article : Google Scholar
|
|
22
|
Bohm D, Keller K, Boehm N, et al: Antibody
microarray analysis of the serum proteome in primary breast cancer
patients. Cancer Biol Ther. 12:772–779. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bertucci F, Birnbaum D and Goncalves A:
Proteomics of breast cancer: principles and potential clinical
applications. Mol Cell Proteomics. 5:1772–1786. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Diamandis EP: Analysis of serum proteomic
patterns for early cancer diagnosis: drawing attention to potential
problems. J Natl Cancer Inst. 96:353–356. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Downes MR, Byrne JC, Dunn MJ, Fitzpatrick
JM, Watson RW and Pennington SR: Application of proteomic
strategies to the identification of urinary biomarkers for prostate
cancer: a review. Biomarkers. 11:406–416. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Radpour R, Barekati Z, Kohler C, Holzgreve
W and Zhong XY: New trends in molecular biomarker discovery for
breast cancer. Genet Test Mol Biomarkers. 13:565–571. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lebrecht A, Boehm D, Schmidt M, Koelbl H,
Schwirz RL and Grus FH: Diagnosis of breast cancer by tear
proteomic pattern. Cancer Genomics Proteomics. 6:177–182.
2009.PubMed/NCBI
|
|
28
|
de Freitas Campos C, Cole N, Van Dyk D, et
al: Proteomic analysis of dog tears for potential cancer markers.
Res Vet Sci. 85:349–352. 2008.PubMed/NCBI
|
|
29
|
Shevchenko A, Loboda A, Ens W, Schraven B,
Standing KG and Shevchenko A: Archived polyacrylamide gels as a
resource for proteome characterization by mass spectrometry.
Electrophoresis. 22:1194–1203. 2001.PubMed/NCBI
|
|
30
|
Perkins DN, Pappin DJ, Creasy DM and
Cottrell JS: Probability-based protein identification by searching
sequence databases using mass spectrometry data. Electrophoresis.
20:3551–3567. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
UniProt Consortium. Ongoing and future
developments at the Universal Protein Resource. Nucleic Acids Res.
39:D214–D219. 2011.PubMed/NCBI
|
|
32
|
Szklarczyk D, Franceschini A, Kuhn M, et
al: The STRING database in 2011: functional interaction networks of
proteins, globally integrated and scored. Nucleic Acids Res.
39:D561–D568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cline MS, Smoot M, Cerami E, et al:
Integration of biological networks and gene expression data using
Cytoscape. Nat Protoc. 2:2366–2382. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Grus FH, Podust VN, Bruns K, et al:
SELDI-TOF-MS ProteinChip array profiling of tears from patients
with dry eye. Invest Ophthalmol Vis Sci. 46:863–876. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nacken W, Roth J, Sorg C and Kerkhoff C:
S100A9/S100A8: Myeloid representatives of the S100 protein family
as prominent players in innate immunity. Microsc Res Tech.
60:569–580. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tamesa MS, Kuramitsu Y, Fujimoto M, et al:
Detection of autoantibodies against cyclophilin A and
triosephosphate isomerase in sera from breast cancer patients by
proteomic analysis. Electrophoresis. 30:2168–2181. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
El Yazidi-Belkoura I, Adriaenssens E,
Vercoutter-Edouart AS, Lemoine J, Nurcombe V and Hondermarck H:
Proteomics of breast cancer: outcomes and prospects. Technol Cancer
Res Treat. 1:287–296. 2002.PubMed/NCBI
|
|
38
|
Gast MC, Schellens JH and Beijnen JH:
Clinical proteomics in breast cancer: a review. Breast Cancer Res
Treat. 116:17–29. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shin BK, Wang H and Hanash S: Proteomics
approaches to uncover the repertoire of circulating biomarkers for
breast cancer. J Mammary Gland Biol Neoplasia. 7:407–413. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhou P, Lowery M, JAD and Kuiken T:
Towards improved myoelectric prosthesis control: high density
surface EMG recording after targeted muscle reinnervation. Conf
Proc IEEE Eng Med Biol Soc. 4:4064–4067. 2005.PubMed/NCBI
|
|
41
|
Böhm D, Keller K, Wehrwein N, et al: Serum
proteome profiling of primary breast cancer indicates a specific
biomarker profile. Oncol Rep. 26:1051–1056. 2011.PubMed/NCBI
|
|
42
|
Oner F, Savas I and Numanoglu N:
Immunoglobulins and complement components in patients with lung
cancer. Tuberk Toraks. 52:19–23. 2004.PubMed/NCBI
|
|
43
|
Liu W, Liu B, Xin L, et al: Down-regulated
expression of complement factor I: a potential suppressive protein
for gastric cancer identified by serum proteome analysis. Clin Chim
Acta. 377:119–126. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gast MC, van Gils CH, Wessels LF, et al:
Influence of sample storage duration on serum protein profiles
assessed by surface-enhanced laser desorption/ionisation
time-of-flight mass spectrometry (SELDI-TOF MS). Clin Chem Lab Med.
47:694–705. 2009.
|
|
45
|
Markiewski MM, DeAngelis RA, Benencia F,
et al: Modulation of the antitumor immune response by complement.
Nat Immunol. 9:1225–1235. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
46
|
Markiewski MM and Lambris JD: Is
complement good or bad for cancer patients? A new perspective on an
old dilemma. Trends Immunol. 30:286–292. 2009. View Article : Google Scholar : PubMed/NCBI
|
